Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

Abstract Introduction This exploratory analysis of FINCH 1 (NCT02889796) examined filgotinib (FIL) efficacy and safety in a subgroup of patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX; MTX-IR) who had four poor prognostic factors (PPFs). Methods Patients with MTX...

Full description

Bibliographic Details
Main Authors:	Bernard G. Combe, Yoshiya Tanaka, Maya H. Buch, Peter Nash, Gerd R. Burmester, Alan J. Kivitz, Beatrix Bartok, Alena Pechonkina, Katrina Xia, Kahaku Emoto, Shungo Kano, Thijs K. Hendrikx, Robert B. M. Landewé, Daniel Aletaha
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2022-10-01
Series:	Rheumatology and Therapy
Subjects:	Filgotinib Poor prognostic factors Adalimumab Methotrexate
Online Access:	https://doi.org/10.1007/s40744-022-00498-x

Similar Items

Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials
by: Yoshiya Tanaka, et al.
Published: (2022-11-01)

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study
by: Bernard G. Combe, et al.
Published: (2023-01-01)

Prevention of Radiographic Progression in Higher-Risk Patients with Rheumatoid Arthritis Using Filgotinib in Phase III Studies: Narrative Review of Post Hoc Analyses
by: Yoshiya Tanaka, et al.
Published: (2023-09-01)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
by: Bernard Combe, et al.
Published: (2022-10-01)

Effect of Filgotinib on Body Mass Index (BMI) and Effect of Baseline BMI on the Efficacy and Safety of Filgotinib in Rheumatoid Arthritis
by: Alejandro Balsa, et al.
Published: (2023-09-01)

ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical Practice
by: Maurizio Benucci, et al.
Published: (2023-08-01)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
by: Martina Biggioggero, et al.
Published: (2019-10-01)

Critical Appraisal of Filgotinib in the Treatment of Ulcerative Colitis: Current Evidence and Place in Therapy
by: Dal Buono A, et al.
Published: (2022-07-01)

Efficacy and safety of selective JAK 1 inhibitor filgotinib in active rheumatoid arthritis patients with inadequate response to methotrexate: comparative study with filgotinib and tocilizumab examined by clinical index as well as musculoskeletal ultrasound assessment (TRANSFORM study): study protocol for a randomized, open-label, parallel-group, multicenter, and non-inferiority clinical trial
by: Toshimasa Shimizu, et al.
Published: (2023-03-01)

Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
by: Toshifumi Hibi, et al.
Published: (2023-01-01)

Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes
by: Mark Genovese, et al.
Published: (2018-03-01)

Validated DBS method for filgotinib quantitation in rat dried blood spots and its application to a pharmacokinetic study in rats
by: Abhishek Dixit, et al.
Published: (2020-06-01)

Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-07-01)

Correction: Filgotinib Modulates Inflammation-Associated Peripheral Blood Protein Biomarkers in Adults with Active Rheumatoid Arthritis and Prior Inadequate Response to Methotrexate
by: Yoshiya Tanaka, et al.
Published: (2023-11-01)

Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
by: René Westhovens, et al.
Published: (2021-07-01)

Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted
by: Maurizio Benucci, et al.
Published: (2022-09-01)

Different Biomarkers of Response to Treatment with Selective Jak-1 Inhibitors in Rheumatoid Arthritis
by: Maurizio Benucci, et al.
Published: (2023-08-01)

Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment
by: Hiroshi Nakase
Published: (2023-07-01)

Treatment response in patients with moderate-to-severe psoriasis who had inadequate response to prior secukinumab
by: Tai-Siang Chiu, et al.
Published: (2019-01-01)

Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Taylor, PC, et al.
Published: (2024)

Impact of filgotinib on pain control in the phase 3 FINCH studies
by: Bruno Fautrel, et al.
Published: (2024-02-01)

Targeted therapy of inflammatory bowel diseases: realities and prospects
by: I. V. Maev, et al.
Published: (2018-04-01)

Correction: Impact of filgotinib on pain control in the phase 3 FINCH studies
Published: (2024-04-01)

Efficacy and safety of filgotinib in patients with moderately active rheumatoid arthritis and an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2024)

Whole blood transcriptional changes following selective inhibition of janus kinase 1 (JAK1) by filgotinib in MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3)
by: Taylor, PC, et al.
Published: (2020)

A subgroup analysis of the efficacy of filgotinib for patients with moderately active RA following an inadequate response to methotrexate
by: Buch, MH, et al.
Published: (2021)

Filgotinib modulates inflammation-associated peripheral blood protein biomarkers in adults with active rheumatoid arthritis and prior inadequate response to methotrexate
by: Tanaka, Y, et al.
Published: (2023)

Safety and effectiveness of adalimumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to prior etanercept
by: Ting-Shun Wang, et al.
Published: (2013-03-01)

Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies
by: Mark C. Genovese, et al.
Published: (2020-06-01)

Adalimumab Originator vs. Biosimilar in Hidradenitis Suppurativa: A Multicentric Retrospective Study
by: Martina Burlando, et al.
Published: (2022-10-01)

Peripheral Protein Biomarker changes following Selective Inhibition of Janus Kinase 1 (JAK1) by Filgotinib in Adults with Moderately-to-severely Active Rheumatoid Arthritis with Prior Inadequate Response to Methotrexate (FINCH1)
by: Taylor, P, et al.
Published: (2020)

Unilateral Verrucous Psoriasis Successfully Treated With Adalimumab
by: Artur Antônio Duarte, et al.
Published: (2024-01-01)

Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study
by: Westhovens, R, et al.
Published: (2016)

Criptosporidiose em paciente com espondilite anquilosante usando adalimumabe Cryptosporidiosis in a patient with ankylosing spondylitis treated with adalimumab
by: Fernando Augusto Chiuchetta
Published: (2010-06-01)

Use of Janus kinase inhibitors in the treatment of immunoinflammatory rheumatic diseases: safety issues
by: B. S. Belov, et al.
Published: (2021-03-01)

Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future
by: Navarini L, et al.
Published: (2020-11-01)

Practical experience of ustekinumab in patients with moderate-to-severe psoriasis who had inadequate therapeutic response to previous tumor necrosis factor blockers
by: Tzu-Chang Wang, et al.
Published: (2015-03-01)

First expirience of adalimumab administration in Russia: preliminary results of an open 24 week study
by: E L Luchichina, et al.
Published: (2008-10-01)

Diffuse large B-cell lymphoma that develops after adalimumab using adalimumab in a patient with psoriasis
by: Esra Yıldırım Bay, et al.
Published: (2021-06-01)

Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)
by: Ayman Elgendi, et al.
Published: (2015-01-01)